These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 21459936

  • 1. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
    van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM.
    J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
    [Abstract] [Full Text] [Related]

  • 2. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, German and Austrian Paediatric Rheumatology Collaborative Study Group.
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [Abstract] [Full Text] [Related]

  • 4. Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab.
    Tarkiainen M, Tynjälä P, Vähäsalo P, Lahdenne P.
    Scand J Rheumatol; 2011 Mar; 40(2):150-2. PubMed ID: 20868307
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 6. The German etanercept registry for treatment of juvenile idiopathic arthritis.
    Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A, Paediatric Rheumatology Collaborative Group.
    Ann Rheum Dis; 2004 Dec; 63(12):1638-44. PubMed ID: 15115709
    [Abstract] [Full Text] [Related]

  • 7. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 8. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept.
    Otten MH, Prince FH, Twilt M, van Rossum MA, Armbrust W, Hoppenreijs EP, Kamphuis S, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Ten Cate R, van Suijlekom-Smit LW.
    J Rheumatol; 2010 Mar; 37(3):665-7. PubMed ID: 20080910
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.
    Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, Ganser G, Horneff G.
    Rheumatology (Oxford); 2012 Aug; 51(8):1407-15. PubMed ID: 22447885
    [Abstract] [Full Text] [Related]

  • 10. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register.
    Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, Koopman-Keemink Y, Gorter SL, Raat H, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2011 Jun; 50(6):1131-6. PubMed ID: 21278067
    [Abstract] [Full Text] [Related]

  • 11. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study.
    Dallocchio A, Canioni D, Ruemmele F, Duquesne A, Scoazec JY, Bouvier R, Paraf F, Languepin J, Wouters CH, Guillot M, Quartier P, Bader-Meunier B, SOFREMIP.
    Rheumatology (Oxford); 2010 Sep; 49(9):1694-8. PubMed ID: 20472717
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.
    Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A, Insalaco A, Cortis E, DE Benedetti F.
    J Rheumatol; 2012 Jun; 39(6):1287-90. PubMed ID: 22589254
    [Abstract] [Full Text] [Related]

  • 14. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [Abstract] [Full Text] [Related]

  • 15. Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics.
    Barthel D, Ganser G, Kuester RM, Onken N, Minden K, Girschick HJ, Hospach A, Horneff G.
    J Rheumatol; 2015 Nov; 42(11):2160-5. PubMed ID: 26373564
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of etanercept in the treatment of juvenile idiopathic arthritis].
    de Inocencio Arocena J, Merino Muñoz R, Alvarez Madrid C, García-Consuegra Molina J.
    An Pediatr (Barc); 2009 Apr; 70(4):354-61. PubMed ID: 19324597
    [Abstract] [Full Text] [Related]

  • 17. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
    Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, van Pelt PA, Kamphuis S, Brinkman DM, Swen WA, Swart JF, Wulffraat NM, Dolman KM, Koopman-Keemink Y, Hoppenreijs EP, Armbrust W, ten Cate R, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
    [Abstract] [Full Text] [Related]

  • 18. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
    Sevcic K, Orban I, Brodszky V, Bazso A, Balogh Z, Poor G, Kiss E.
    Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
    [Abstract] [Full Text] [Related]

  • 19. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 20. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept.
    Solari N, Palmisani E, Consolaro A, Pistorio A, Viola S, Buoncompagni A, Gattorno M, Picco P, Ruperto N, Malattia C, Martini A, Ravelli A.
    J Rheumatol; 2013 Feb; 40(2):192-200. PubMed ID: 23204218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.